DERM

+ Watchlist + Portfolio

Journey Medical Corp.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $6.81
52-Week Range: $4.31 – $9.56
Market Cap: $211.40M
P/E (TTM): —
EPS (TTM): -0.22
Dividend Yield: —

Advanced Metrics

Price/Book: 6.45
PEG Ratio: —
Return on Equity: -23.77%
Return on Assets: -2.10%
Gross Margin: 65.45%
Operating Margin: 2.46%
Profit Margin: -8.95%
Current Ratio: 1.59
Debt/Equity: 0.80
Total Debt: $25.54M
Free Cash Flow: $-5.46M
Revenue Growth: 23.30%
Earnings Growth: —
Enterprise Value: $192.11M

DERM Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$73.67M	$79.18M	$56.13M	$61.86M
Cost of Revenue	$30.77M	$22.89M	$20.88M	$20.92M
Gross Profit	$42.89M	$56.29M	$35.26M	$40.93M
Research & Development	$10.94M	$7.54M	$9.86M	$480.00K
Selling, General & Admin	$59.47M	$43.91M	$40.20M	$44.37M
Operating Expenses	$70.41M	$55.22M	$53.48M	$49.11M
Operating Income	-$27.52M	$1.07M	-$18.23M	-$8.17M
EBITDA	-$23.18M	$1.92M	-$8.40M	-$3.33M
Pretax Income	-$29.57M	-$3.63M	-$14.61M	-$11.37M
Income Tax	$63.00K	$221.00K	$61.00K	$60.00K
Net Income	-$29.63M	-$3.85M	-$14.67M	-$11.43M
Diluted EPS	-1.69	-0.21	-0.72	-0.47
Diluted Shares	17.53M	18.23M	20.43M	24.50M

DERM Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$32.00M	$27.44M	$20.30M	$24.09M
Receivables	$28.21M	$15.22M	$10.23M	$29.78M
Inventory	$14.16M	$10.21M	$14.43M	$9.62M
Current Assets	$77.68M	$56.45M	$48.18M	$66.87M
Total Assets	$105.16M	$76.85M	$80.24M	$94.59M
Current Liabilities	$66.83M	$41.87M	$35.17M	$37.44M
Long-Term Debt	$19.83M	$14.62M	$24.88M	$25.28M
Total Debt	$22.96M	$14.73M	$25.08M	$25.40M
Total Liabilities	$88.18M	$56.50M	$60.17M	$62.74M
Retained Earnings	-$68.50M	-$72.36M	-$87.03M	-$98.46M
Shareholders' Equity	$16.98M	$20.35M	$20.07M	$31.85M
Working Capital	$10.85M	$14.59M	$13.00M	$29.43M
Net Debt	—	—	$4.57M	$1.19M

DERM Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$13.53M	$5.24M	-$9.13M	-$12.44M
Capital Expenditure	-$20.00M	-$5.00M	-$15.00M	—
Free Cash Flow	-$33.53M	$240.00K	-$24.13M	-$12.44M
Depreciation & Amortisation	$4.37M	$3.85M	$3.52M	$4.35M
Stock-Based Compensation	$4.42M	$2.61M	$6.10M	$6.29M
Investing Cash Flow	-$20.00M	-$5.00M	-$15.00M	$0.00
Financing Cash Flow	$16.46M	-$4.80M	$16.99M	$16.23M
Net Change in Cash	-$17.08M	-$4.56M	-$7.13M	$3.79M

DERM Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$13.14M	$15.01M	$17.63M	$16.08M	$15.96M
Cost of Revenue	$4.79M	$4.94M	$5.75M	$5.44M	$6.22M
Gross Profit	$8.35M	$10.07M	$11.88M	$10.64M	$9.74M
Research & Development	$39.00K	$0.00	$287.00K	$154.00K	$0.00
Selling, General & Admin	$10.57M	$11.88M	$12.05M	$9.86M	$10.11M
Operating Expenses	$11.67M	$12.95M	$13.40M	$11.08M	$11.23M
Operating Income	-$3.32M	-$2.88M	-$1.53M	-$443.00K	-$1.49M
EBITDA	-$2.10M	-$1.71M	-$292.00K	$774.00K	-$189.00K
Pretax Income	-$4.07M	-$3.74M	-$2.31M	-$1.25M	-$2.23M
Income Tax	$0.00	$60.00K	$0.00	$0.00	$0.00
Net Income	-$4.07M	-$3.80M	-$2.31M	-$1.25M	-$2.23M
Diluted EPS	-0.18	-0.16	-0.09	—	-0.08
Diluted Shares	22.61M	23.29M	24.96M	—	27.31M

DERM Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$21.07M	$20.29M	$24.95M	$24.09M	$27.22M
Receivables	$18.02M	$15.64M	$17.98M	$29.78M	$24.99M
Inventory	$12.50M	$12.85M	$11.82M	$9.62M	$9.29M
Current Assets	$53.99M	$51.27M	$56.39M	$66.87M	$64.97M
Total Assets	$84.96M	$81.16M	$85.19M	$94.59M	$91.53M
Current Liabilities	$40.22M	$40.48M	$39.72M	$37.44M	$37.83M
Long-Term Debt	$23.11M	$21.36M	$19.53M	$25.28M	$22.87M
Total Debt	$25.17M	$25.28M	$25.30M	$25.40M	$25.47M
Total Liabilities	$63.42M	$61.91M	$59.29M	$62.74M	$60.70M
Retained Earnings	-$91.10M	-$94.90M	-$97.21M	-$98.46M	-$100.69M
Shareholders' Equity	$21.54M	$19.25M	$25.90M	$31.85M	$30.83M
Working Capital	$13.76M	$10.79M	$16.67M	$29.43M	$27.14M
Net Debt	$3.91M	$4.82M	$211.00K	$1.19M	—

DERM Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$2.83M	-$942.00K	-$2.38M	-$6.28M	$2.91M
Free Cash Flow	-$2.83M	-$942.00K	-$2.38M	-$6.28M	$2.91M
Depreciation & Amortisation	$1.09M	$1.09M	$1.09M	$1.09M	$1.15M
Stock-Based Compensation	$1.32M	$1.34M	$1.85M	$1.77M	$989.00K
Financing Cash Flow	$3.60M	$165.00K	$7.04M	$5.43M	$220.00K
Net Change in Cash	$765.00K	-$777.00K	$4.66M	-$858.00K	$3.13M

Market Snapshot

About

Journey Medical Corp. is a specialty pharmaceutical company focused on dermatology products. The company develops, markets, and sells prescription and over-the-counter products for treating various skin conditions. Journey Medical's portfolio includes branded prescription dermatology drugs acquired from larger pharmaceutical companies or developed through partnerships. The company targets underserved segments of the dermatology market with an experienced commercial team.